Home > Drugs A – Z > Fingolimod (By mouth)

Fingolimod (By mouth)

Treats flare-ups of multiple sclerosis.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Fingolimod is used to treat the relapsing forms of multiple sclerosis (MS). This medicine will not cure MS, but it may slow some disabling effects and decrease the number of relapses of the disease. This medicine is available only with your doctor's prescription… Read more
Brand names include
Gilenya
Drug classes About this
Immune Modulator

What works? Research summarized

Evidence reviews

Fingolimod (New Therapeutic Indication) -- Benefit Assessment According to §35a Social Code Book V [Internet]

The aim of this report was to assess the added benefit of fingolimod in comparison with the appropriate comparator therapy (ACT) for the expansion of the therapeutic indication of fingolimod approved in May 2014. This expansion includes adult patients with highly active relapsing remitting multiple sclerosis (RRMS) who have received pretreatment with a disease-modifying therapy other than interferon beta (IFN-β).

Fingolimod (Addendum to Commission A14-21) [Internet]

On 12 November 2014 (supplemented on 18 November 2014), the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to conduct a supplementary assessment for Commission A14-21 (benefit assessment of fingolimod).

Fingolimod -- Benefit Assessment According to §35a Social Code Book V [Internet]

In the benefit assessment fingolimod was compared with

See all (21)

Summaries for consumers

Fingolimod (Gilenya) for multiple sclerosis: Fingolimod (Gilenya) after glatiramer acetate therapy

In 2016, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of fingolimod compared with the standard therapies for people with highly active relapsing remitting multiple sclerosis (RRMS).The following results apply to patients who still had active multiple sclerosis despite using glatiramer acetate therapy at a sufficient.For this group of patients, data from one study was available: 17 of the participants took fingolimod and 25 had the standard therapy with interferon beta as follow-up treatment.

Fingolimod (Gilenya) for multiple sclerosis: Fingolimod (Gilenya) for rapidly evolving relapsing-remitting multiple sclerosis

In 2015, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of fingolimod compared with the standard therapies for people with rapidly evolving severe RRMS. For these people, fingolimod is an alternative to standard therapies that use interferon beta or glatiramer acetate.IQWiG assessed the data from a study involving a total of 121 patients. Half of the participants were treated with fingolimod, while the rest used interferon beta.

Comparing Fingolimod with other MS Drugs

How does fingolimod compare in multiple sclerosis?

See all (13)

PubMed Health Blog...

read all...